Gilead has returned the rights to a cancer candidate it licensed from Arcus Biosciences in a $725 million, multiprogram deal, ...

Andrea Delbarba and Claudia Finetti of Bugnion SpA explain how supplementary protection certificates extend pharmaceutical ...

Fintel reports that on August 6, 2025, Leerink Partners initiated coverage of Xilio Therapeutics (NasdaqGS:XLO) with a ...

The largest group of Black physicians, thought leaders, and celebrities were in one room to have a needed discussion about HIV.

The company had earlier said that its Q2 financial results were expected to take a $61 million hit due to acquired in-process ...

Analysts expect Gilead Sciences to report an earnings per share (EPS) of $1.95. Investors in Gilead Sciences are eagerly ...

Orchestrate agents autonomously with A2A: Aisera Unify natively supports A2A protocol, enabling real-time coordination across AI agents. Agents are discovered via dynamic Agent Cards backed by the ...

Now, let’s get to the juicy part. In a dataset that goes back to January 2019, the 4-6-U sequence has flashed 13 times on a ...

Patients with HIV had lower adherence to pre-exposure prophylaxis (PrEP) if they lived in areas with the lowest disadvantage.

Magrolimab triple therapy falls short of expectations in a study of previously untreated acute myeloid leukemia.

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) will be reporting results this Thursday after market close. Here’s ...

The stock's fall snapped a two-day winning streak.